Literature DB >> 26561028

In Vivo Evaluation of a Bombesin Analogue Labeled with Ga-68 and Co-55/57.

Johan Hygum Dam1, Birgitte Brinkmann Olsen2, Christina Baun2, Poul-Flemming Høilund-Carlsen2,3, Helge Thisgaard2,3.   

Abstract

PURPOSE: The purpose of this study was to apply an analogue of bombesin, NOTA-AMBA, labeled with Co-55 or Ga-68, for preclinical imaging of prostate cancer. PROCEDURES: The peptide NOTA-AMBA was labeled with Ga-68 or Co-55 by microwave irradiation. Biodistribution in xenograft mice (PC3) was performed at 1, 4, and 24 h (only cobalt at 24 h) using a fixed amount of peptide. Four weeks post-inoculation, xenograft mice were positron emission tomography/X-ray computed tomography scanned after tail vein injection of [(68)Ga]NOTA-AMBA or [(55)Co]NOTA-AMBA.
RESULTS: Labeling with Ga-68 and Co-55/57 was achieved in yields greater than 90 %. A radiochemical purity (RCP) of 95 and 90 % were obtained for Ga-68 and Co-55, respectively. Both radiopeptides showed high uptake in the intestines, stomach, pancreas, and in the tumor ([(68)Ga]NOTA-AMBA, 10.3 %ID/g at 1 h to 6.4 %ID/g at 4 h; [(57)Co]NOTA-AMBA, 8.2 %ID/g at 1 h to 5.3%ID/g at 24 h). Normal tissue cleared over time improving tumor-to-background ratios.
CONCLUSIONS: NOTA-AMBA was labeled in high yields and RCP with Ga-68 and Co-55/57. High tumor uptake in a subcutaneous mouse prostate cancer model was observed. At 24 h, [(55/57)Co]NOTA-AMBA showed better tumor-to-organ ratios than [(68)Ga]NOTA-AMBA at both 1 and 4 h post-injection. Hence, for imaging, [(55)Co]NOTA-AMBA was found to be superior compared to [(68)Ga]NOTA-AMBA.

Entities:  

Keywords:  AMBA; Bombesin; Cobalt-55; Gallium-68; PET; Positron emission tomography; Prostate cancer

Mesh:

Substances:

Year:  2016        PMID: 26561028     DOI: 10.1007/s11307-015-0911-z

Source DB:  PubMed          Journal:  Mol Imaging Biol        ISSN: 1536-1632            Impact factor:   3.488


  32 in total

1.  Evaluation of radiolabelled bombesin analogues for receptor-targeted scintigraphy and radiotherapy.

Authors:  W A Breeman; L J Hofland; M de Jong; B F Bernard; A Srinivasan; D J Kwekkeboom; T J Visser; E P Krenning
Journal:  Int J Cancer       Date:  1999-05-17       Impact factor: 7.396

2.  Multimodality imaging and preclinical evaluation of 177Lu-AMBA for human prostate tumours in a murine model.

Authors:  I-Hsiang Liu; Chih-Hsien Chang; Chung-Li Ho; Shu-Pei Chiu; Wan-Chi Lee; Tsui-Jung Chang; Liang-Cheng Chen; Yu-Hsien Wu; Cheng-Hui Chuang; Ying-Kai Fu; Te-Wei Lee
Journal:  Anticancer Res       Date:  2010-10       Impact factor: 2.480

3.  Prostate cancer screening: the problem of overdiagnosis and lessons to be learned from breast cancer screening.

Authors:  S Ciatto; M Zappa; R Bonardi; G Gervasi
Journal:  Eur J Cancer       Date:  2000-07       Impact factor: 9.162

Review 4.  Gastrin-releasing peptide receptor as a molecular target in experimental anticancer therapy.

Authors:  D B Cornelio; R Roesler; G Schwartsmann
Journal:  Ann Oncol       Date:  2007-03-09       Impact factor: 32.976

5.  Development of a potent DOTA-conjugated bombesin antagonist for targeting GRPr-positive tumours.

Authors:  Rosalba Mansi; Xuejuan Wang; Flavio Forrer; Beatrice Waser; Renzo Cescato; Keith Graham; Sandra Borkowski; Jean Claude Reubi; Helmut R Maecke
Journal:  Eur J Nucl Med Mol Imaging       Date:  2010-08-18       Impact factor: 9.236

6.  Automated synthesis, characterization and biological evaluation of [(68)Ga]Ga-AMBA, and the synthesis and characterization of (nat)Ga-AMBA and [(67)Ga]Ga-AMBA.

Authors:  Aldo Cagnolini; Jianqing Chen; Kimberly Ramos; Tina Marie Skedzielewski; Laura E Lantry; Adrian D Nunn; Rolf E Swenson; Karen E Linder
Journal:  Appl Radiat Isot       Date:  2010-06-30       Impact factor: 1.513

Review 7.  Nuclear imaging of prostate cancer with gastrin-releasing-peptide-receptor targeted radiopharmaceuticals.

Authors:  H J K Ananias; I J de Jong; R A Dierckx; C van de Wiele; W Helfrich; P H Elsinga
Journal:  Curr Pharm Des       Date:  2008       Impact factor: 3.116

Review 8.  Peptide receptor imaging of prostate cancer with radiolabelled bombesin analogues.

Authors:  R P J Schroeder; W M van Weerden; C Bangma; E P Krenning; M de Jong
Journal:  Methods       Date:  2009-05-03       Impact factor: 3.608

9.  Evaluation of cobalt-labeled octreotide analogs for molecular imaging and auger electron-based radionuclide therapy.

Authors:  Helge Thisgaard; Birgitte Brinkmann Olsen; Johan Hygum Dam; Peter Bollen; Jan Mollenhauer; Poul Flemming Høilund-Carlsen
Journal:  J Nucl Med       Date:  2014-05-29       Impact factor: 10.057

10.  Radiolabeled peptides: valuable tools for the detection and treatment of cancer.

Authors:  M Fani; H R Maecke; S M Okarvi
Journal:  Theranostics       Date:  2012-05-16       Impact factor: 11.556

View more
  11 in total

1.  Cyclotron production and radiochemical separation of 55Co and 58mCo from 54Fe, 58Ni and 57Fe targets.

Authors:  H F Valdovinos; R Hernandez; S Graves; P A Ellison; T E Barnhart; C P Theuer; J W Engle; W Cai; R J Nickles
Journal:  Appl Radiat Isot       Date:  2017-09-06       Impact factor: 1.513

2.  Novel Gastrin-Releasing Peptide Receptor Targeted Near-Infrared Fluorescence Dye for Image-Guided Surgery of Prostate Cancer.

Authors:  Amerigo Pagoto; Francesca Garello; Giada Maria Marini; Martina Tripepi; Francesca Arena; Paola Bardini; Rachele Stefania; Stefania Lanzardo; Giovanni Valbusa; Francesco Porpiglia; Matteo Manfredi; Silvio Aime; Enzo Terreno
Journal:  Mol Imaging Biol       Date:  2020-02       Impact factor: 3.488

Review 3.  Expanding the PET radioisotope universe utilizing solid targets on small medical cyclotrons.

Authors:  K J H George; S Borjian; M C Cross; J W Hicks; P Schaffer; M S Kovacs
Journal:  RSC Adv       Date:  2021-09-21       Impact factor: 4.036

Review 4.  PET radiometals for antibody labeling.

Authors:  Eduardo Aluicio-Sarduy; Paul A Ellison; Todd E Barnhart; Weibo Cai; Robert Jerry Nickles; Jonathan W Engle
Journal:  J Labelled Comp Radiopharm       Date:  2018-03-12       Impact factor: 1.921

5.  TM1-IR680 peptide for assessment of surgical margin and lymph node metastasis in murine orthotopic model of oral cancer.

Authors:  Annie A Suganya S; K J Kochurani; Madhumathy G Nair; Jiss Maria Louis; Santhosh Sankaran; R Rajagopal; K Santhosh Kumar; Parvin Abraham; Balagopal P G; Paul Sebastian; Thara Somananthan; Tessy Thomas Maliekal
Journal:  Sci Rep       Date:  2016-11-09       Impact factor: 4.379

6.  High Contrast PET Imaging of GRPR Expression in Prostate Cancer Using Cobalt-Labeled Bombesin Antagonist RM26.

Authors:  Bogdan Mitran; Helge Thisgaard; Ulrika Rosenström; Johan Hygum Dam; Mats Larhed; Vladimir Tolmachev; Anna Orlova
Journal:  Contrast Media Mol Imaging       Date:  2017-08-10       Impact factor: 3.161

7.  The use of radiocobalt as a label improves imaging of EGFR using DOTA-conjugated Affibody molecule.

Authors:  Javad Garousi; Ken G Andersson; Johan H Dam; Birgitte B Olsen; Bogdan Mitran; Anna Orlova; Jos Buijs; Stefan Ståhl; John Löfblom; Helge Thisgaard; Vladimir Tolmachev
Journal:  Sci Rep       Date:  2017-07-20       Impact factor: 4.379

8.  Selection of an optimal macrocyclic chelator improves the imaging of prostate cancer using cobalt-labeled GRPR antagonist RM26.

Authors:  Bogdan Mitran; Helge Thisgaard; Sara Rinne; Johan Hygum Dam; Frishta Azami; Vladimir Tolmachev; Anna Orlova; Ulrika Rosenström
Journal:  Sci Rep       Date:  2019-11-19       Impact factor: 4.379

9.  Benefit of Later-Time-Point PET Imaging of HER3 Expression Using Optimized Radiocobalt-Labeled Affibody Molecules.

Authors:  Sara S Rinne; Charles Dahlsson Leitao; Zahra Saleh-Nihad; Bogdan Mitran; Vladimir Tolmachev; Stefan Ståhl; John Löfblom; Anna Orlova
Journal:  Int J Mol Sci       Date:  2020-03-13       Impact factor: 5.923

Review 10.  Prognostic and Theranostic Applications of Positron Emission Tomography for a Personalized Approach to Metastatic Castration-Resistant Prostate Cancer.

Authors:  Luca Filippi; Viviana Frantellizzi; Agostino Chiaravalloti; Mariano Pontico; Maria Silvia De Feo; Ferdinando Corica; Melissa Montebello; Orazio Schillaci; Giuseppe De Vincentis; Oreste Bagni
Journal:  Int J Mol Sci       Date:  2021-03-16       Impact factor: 5.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.